Vismodegib (GDC-0449)

For research use only. Not for use in humans.

目录号：S1082 中文名称：维莫德吉

Vismodegib (GDC-0449) Chemical Structure

CAS No. 879085-55-9

Vismodegib (GDC-0449)是一种新型有效的，特异性hedgehog抑制剂，无细胞试验中IC50为3 nM，也会抑制P-gp，IC50为3.0μM。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1179.52	现货
5mg	RMB 730.63	现货
50mg	RMB 3046.91	现货
200mg	RMB 8763.3	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Vismodegib (GDC-0449)发表文献153篇：

Nature, 2021, 10.1038/s41586-021-03703-z

PubMed: 34234347 ( click the link to review the publication )

Nat Med, 2018, 24(3):271-281

PubMed: 29400712 ( click the link to review the publication )

Nat Med, 2018, 24(11):1752-1761

PubMed: 30349086 ( click the link to review the publication )

Nat Med, 2017, 23(10):1191-1202

PubMed: 28892064 ( click the link to review the publication )

Nature, 2016, 535(7613):517-22

PubMed: 27437577 ( click the link to review the publication )

Nature, 2014, 3;511(7507):90-3.

PubMed: 24870236 ( click the link to review the publication )

Nat Med, 2014, 20(9):1035-42

PubMed: 25150496 ( click the link to review the publication )

Nat Med, 2014, 20(7):732-40

PubMed: 24973920 ( click the link to review the publication )

Cancer Cell, 2014, 26(1):33-47

PubMed: 24954133 ( click the link to review the publication )

Gastroenterology, 2012, 143(5):1319-29.e1-11

PubMed: 22885334 ( click the link to review the publication )

Adv Sci (Weinh), 2021, 8(14):2100626

PubMed: 34306986 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(16)8372

PubMed: 34445078 ( click the link to review the publication )

Genes (Basel), 2021, 12(1)E120

PubMed: 33477943 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Commun Biol, 2021, 4(1):544

PubMed: 33972689 ( click the link to review the publication )

Cell Death Dis, 2021, 12(2):199

PubMed: 33608498 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5079

PubMed: 33033234 ( click the link to review the publication )

Nucleic Acids Res, 2020, 48(18):10342-10352

PubMed: 32894284 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Theranostics, 2020, 10(4):1719-1732

PubMed: 32042332 ( click the link to review the publication )

Cancer Res, 2020, 5 pii: canres

PubMed: 32371475 ( click the link to review the publication )

Cells, 2020, 10(1)E53

PubMed: 33396427 ( click the link to review the publication )

Aging (Albany NY), 2020, 10.18632/aging.103230

PubMed: 32544883 ( click the link to review the publication )

Carcinogenesis, 2020, 41(7):993-1004

PubMed: 31740922 ( click the link to review the publication )
Front Oncol, 2020, 10:563838

PubMed: 33312948 ( click the link to review the publication )

Front Cell Neurosci, 2020, 14:575690

PubMed: 33343302 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00514-2

PubMed: 32958873 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00504-4

PubMed: 32855528 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Dev Biol, 2020, 457(1):128-139

PubMed: 31550483 ( click the link to review the publication )

PLoS One, 2020, 29;15(4):e0231762

PubMed: 32348319 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Oncotarget, 2020, 11(33):3174-3187

PubMed: 32913560 ( click the link to review the publication )

JCI Insight, 2020,

PubMed: 32814713 ( click the link to review the publication )

Sci Rep, 2020, 10(1):13400

PubMed: 32770014 ( click the link to review the publication )

J Clin Invest, 2019, 129(12):5151-5162

PubMed: 31638600 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(26):12986-12995

PubMed: 31182587 ( click the link to review the publication )

J Invest Dermatol, 2019, 139(7):1439-1448

PubMed: 30707899 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31601026 ( click the link to review the publication )

Cell Death Dis, 2019, 10(12):952

PubMed: 31844040 ( click the link to review the publication )

Endocr Relat Cancer, 2019, 10.1530/ERC-18-0538

PubMed: 30645190 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):364

PubMed: 31791391 ( click the link to review the publication )

ACS Chem Biol, 2019, 14(3):348-355

PubMed: 30763062 ( click the link to review the publication )

Lab Invest, 2019, 10.1038/s41374-019-0346-2

PubMed: 31758086 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(17)

PubMed: 31480400 ( click the link to review the publication )

Sci Rep, 2019, 9(1):3353

PubMed: 30833624 ( click the link to review the publication )
Sci Rep, 2019, 9(1):19623

PubMed: 31873117 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

J Biol Chem, 2019, 294(25):9787-9798

PubMed: 30992365 ( click the link to review the publication )

J Biol Chem, 2019, 294(9):3284-3293

PubMed: 30573683 ( click the link to review the publication )

Front Pharmacol, 2019, 10:89

PubMed: 30846937 ( click the link to review the publication )

Front Genet, 2019,

PubMed: 31867038 ( click the link to review the publication )

Toxicol Lett, 2019, 313:30-41

PubMed: 31181250 ( click the link to review the publication )

Oncol Rep, 2019, 41(1):437-446

PubMed: 30365081 ( click the link to review the publication )

PLoS One, 2019, 14(12):e0226570

PubMed: 31860685 ( click the link to review the publication )

PLoS One, 2019, 14(9):e0214901

PubMed: 31539380 ( click the link to review the publication )

Int J Oral Sci, 2019, 11(1):3

PubMed: 30783111 ( click the link to review the publication )

Phytomedicine, 2019, 67:153163

PubMed: 31901891 ( click the link to review the publication )

Nat Cell Biol, 2018, 20(8):909-916

PubMed: 30038251 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2897

PubMed: 30042390 ( click the link to review the publication )

Sci Signal, 2018, 11(547)eaau5147

PubMed: 30206138 ( click the link to review the publication )

Cell Chem Biol, 2018, 25(4):357-369

PubMed: 29396292 ( click the link to review the publication )

Oncoimmunology, 2018, 8(3):1548241

PubMed: 30723576 ( click the link to review the publication )

Eur J Med Chem, 2018, 156:554-562

PubMed: 30025349 ( click the link to review the publication )

Toxicol Sci, 2018, 166(2):394-408

PubMed: 30496568 ( click the link to review the publication )

Bone Res, 2018, 6:30

PubMed: 30345151 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):6107-6114

PubMed: 29731842 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(44):E9386-E9394

PubMed: 29078327 ( click the link to review the publication )

Cancer Res, 2017, 77(12):3217-3230

PubMed: 28515149 ( click the link to review the publication )
J Control Release, 2017, 261:105-112

PubMed: 28662901 ( click the link to review the publication )

Oncogene, 2017, 36(45):6306-6314

PubMed: 28714964 ( click the link to review the publication )

Oncogene, 2017, 36(32):4641-4652

PubMed: 28368412 ( click the link to review the publication )

Br J Cancer, 2017, 117(9):1314-1325

PubMed: 28881358 ( click the link to review the publication )

Cancer Discov, 2017,

PubMed: 28923910 ( click the link to review the publication )

Sci Rep, 2017, 7(1):3815

PubMed: 28630423 ( click the link to review the publication )

Sci Rep, 2017, 7(1):13379

PubMed: 29042665 ( click the link to review the publication )

Am J Pathol, 2017, 187(5):1068-1092

PubMed: 28315313 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2017, 79(2):411-420

PubMed: 28110457 ( click the link to review the publication )

Anticancer Drugs, 2017, 28(10):1106-1117

PubMed: 28799948 ( click the link to review the publication )

J Craniofac Surg, 2017, 28(6):1607-1614

PubMed: 28863112 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103744-103757

PubMed: 29262597 ( click the link to review the publication )

Oncotarget, 2017, 8(47):82123-82143

PubMed: 29137250 ( click the link to review the publication )

Cell Cycle, 2017, 16(14):1357-1365

PubMed: 28562206 ( click the link to review the publication )

Oncotarget, 2017, 8(30):48660-48670

PubMed: 27750213 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29371980 ( click the link to review the publication )

Cell Mol Immunol, 2017, 14(2):214-222

PubMed: 26189371 ( click the link to review the publication )

Hepatology, 2016, 63(4):1155-69

PubMed: 26473743 ( click the link to review the publication )

NATURE COMMUNICATIONS, 2016, 10.1038/ncomms10993

PubMed: 27001906 ( click the link to review the publication )

Nat Commun, 2016, 7:11151

PubMed: 27039827 ( click the link to review the publication )

Cancer Res, 2016, 76(18):5538-49

PubMed: 27488530 ( click the link to review the publication )

Cancer Res, 2016, 76(24):7168-7180

PubMed: 27913436 ( click the link to review the publication )

Arthritis Rheumatol, 2016, 68(10):2432-43

PubMed: 27159076 ( click the link to review the publication )

Cell Death Dis, 2016, 7(9):e2376

PubMed: 27899820 ( click the link to review the publication )
Stem Cells, 2016, 34(1):55-66

PubMed: 26418365 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

Oxid Med Cell Longev, 2016, 2016:9826726

PubMed: 27143997 ( click the link to review the publication )

Sci Rep, 2016, 6:24039

PubMed: 27041063 ( click the link to review the publication )

Sci Rep, 2016, 6:22540

PubMed: 26931153 ( click the link to review the publication )

Clin Lung Cancer, 2016, 17(4):301-8

PubMed: 26762562 ( click the link to review the publication )

Prog Biophys Mol Biol, 2016, 122(2):101-111

PubMed: 27179639 ( click the link to review the publication )

Mol Med Rep, 2016, 13(2):1434-40

PubMed: 26676867 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84286-84298

PubMed: 27713179 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 26936993 ( click the link to review the publication )

Sci Rep, 2016, 6:20189

PubMed: 26846842 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(20):4686-97

PubMed: 26124204 ( click the link to review the publication )

PLoS Genet, 2015, 11(6):e1005214

PubMed: 26091072 ( click the link to review the publication )

Development, 2015, 142(19):3374-82

PubMed: 26293299 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(4):1337-52

PubMed: 26101701 ( click the link to review the publication )

Sci Rep, 2015, 5:16232

PubMed: 26549569 ( click the link to review the publication )

Sci Rep, 2015, 5:14135

PubMed: 26370741 ( click the link to review the publication )

Mol Carcinog, 2015, 10.1002/mc.22300

PubMed: 25728352 ( click the link to review the publication )

Breast Cancer Res Treat, 2015,

PubMed: 25904215 ( click the link to review the publication )

Cell Cycle, 2015, 14(1):31-45

PubMed: 25496115 ( click the link to review the publication )

Cell Cycle, 2015, 747:71-87

PubMed: ( click the link to review the publication )

PLoS One, 2015, 10(3):e0116390

PubMed: 25775002 ( click the link to review the publication )

PLoS One, 2015, 10(10):e0139830

PubMed: 26439749 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 457(3):318-23

PubMed: ( click the link to review the publication )
Oncol Lett, 2015, 9(6):2675-2679

PubMed: 26137127 ( click the link to review the publication )

Oncotarget, 2015, 6(30):28895-910

PubMed: 26336820 ( click the link to review the publication )

Sci Rep, 2015, 5:7915

PubMed: 25604826 ( click the link to review the publication )

Cell Rep, 2014, 8(5):1405-18

PubMed: 25176648 ( click the link to review the publication )

J Exp Clin Cancer Res, 2014, 33:34

PubMed: 24758269 ( click the link to review the publication )

Mol Pharmacol, 2014, 83(5):1020-9

PubMed: 23448715 ( click the link to review the publication )

Ann Surg Oncol, 2014, 21(8):2684-98

PubMed: 24682719 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2014, 21(8):2684-98

PubMed: 24450438 ( click the link to review the publication )

Pharmacol Res Perspect, 2014, 2(3):e00043

PubMed: 25505589 ( click the link to review the publication )

Universite Pierre et Marie Curie , 2014, LEPRIEUR EP

PubMed: ( click the link to review the publication )

Pharmacology Research Perspectives, 2014, 10.1002/prp2.43

PubMed: ( click the link to review the publication )

Gut, 2013, 62(2):299-309

PubMed: 22362915 ( click the link to review the publication )

Hepatology, 2013, 58(4):1362-74

PubMed: 23703673 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(6):1422-32

PubMed: 23319824 ( click the link to review the publication )

Thyroid, 2013, 23(9):1119-26

PubMed: 23410206 ( click the link to review the publication )

Cancer Lett, 2013, 329(1):74-83

PubMed: 23111106 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(1):37-48

PubMed: 24233399 ( click the link to review the publication )

J Thorac Cardiovasc Surg, 2013, 147(1):508-16

PubMed: 24094913 ( click the link to review the publication )

Drug Metab Dispos, 2013, 41(10):1805-12

PubMed: 23868912 ( click the link to review the publication )

PLoS One, 2013, 8(6):e65032

PubMed: 23762282 ( click the link to review the publication )

PLoS One, 2013, 8(9):e74141

PubMed: 24066108 ( click the link to review the publication )

PLoS One, 2013, 8(3):e57346

PubMed: 23483902 ( click the link to review the publication )

Hematology, 2013, 88(4):265-72

PubMed: 23475625 ( click the link to review the publication )

Liver Int, 2013, 33(1):149-61

PubMed: 23121638 ( click the link to review the publication )
Gut, 2012, 61(9):1323-9

PubMed: 22427237 ( click the link to review the publication )

Cancer Res, 2012, 72(22):5912-20

PubMed: 22986746 ( click the link to review the publication )

ACS Chem Biol, 2012, 7(6):1040-8

PubMed: 22554036 ( click the link to review the publication )

Stem Cells Dev, 2012, 21(16):2939-48

PubMed: 22642671 ( click the link to review the publication )

Chem Biol, 2012, 19(8):972-82

PubMed: 22921064 ( click the link to review the publication )

Hepatology, 2011, 54(5):1580-90

PubMed: 21793033 ( click the link to review the publication )

Mol Cancer, 2011, 10:66

PubMed: 21619683 ( click the link to review the publication )

PLoS One, 2011, 6(9):e23943

PubMed: 21912653 ( click the link to review the publication )

J Neurooncol, 2011, 105(3):475-83

PubMed: 21633906 ( click the link to review the publication )

产品安全说明书

Hedgehog/Smoothened抑制剂选择性比较

生物活性

产品描述

Vismodegib (GDC-0449)是一种新型有效的，特异性hedgehog抑制剂，无细胞试验中IC50为3 nM，也会抑制P-gp，IC50为3.0μM。

靶点

Hedgehog ^[1]
(Cell-free assay)

3 nM

体外研究

GDC-0449有效抑制hedgehog通路，是一种新型及特定合成的小分子抑制剂，IC50为3nM。^[1] GDC-0449作用于Hedgehog信号通路，阻断Hedgehog配位体，即细胞表面受体PTCH 及SMO的活性，从而阻断Hedgehog信号通路。在组织生长和修复方面，Hedgehog信号通路意义重大。Hedgehog通路信号的异常激活，及不受控制的细胞增殖，可能与Hedgehog配位体，即细胞表面受体PTCH 及SMO的突变有关。在体外，GDC-0449在不抑制胰脏细胞增殖的前提下阻止原代胰脏移植物的生长，这项结果最近已经应用到临床。GDC-0449也抑制ABCG2, P-糖蛋白, 及和MDR有关联的重要MRP1 ABC载体。GDC-0449也阻断其他多种ABC载体。ABC载体属于一个膜蛋白家族，它的过量表达和耐药性有关，这也是治疗癌症的一个重大障碍。GDC-0449强抑制两种ABC载体，ABCG2/BCRP和ABCB1/P-糖蛋白，也温和抑制ABCC1/MRP1。在ABCG2过量表达的HEK293细胞中, GDC-0449可以提高荧光ABCG2底物BODIPY-哌唑嗪的保持力，也可用米托蒽醌再次处理这些细胞，产生抗肿瘤的ABCG2底物。实验使Madin-Darby犬的肾脏细胞中过量表达P糖蛋白或者MRP1，GDC-0449 提高了钙黄绿素-AM的保持力，然后载用秋水仙素处理这些细胞。另外，用米托蒽醌,托泊替康,SN-38处理的过量表达ABCG2的人类非小细胞肺癌细胞NCI-H460/par和NCI-H460/MX20，用GDC-0449再次处理。GDC-0449 作用于ABCG2 和 Pgp 的IC50值分别为1.4μM和 3.0 μM。^[2]GDC-0449 改变细胞内Ca²⁺ 平衡，且作用于抗cisplatin的肺癌细胞，抑制细胞生长。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
IGROV-1	M3;ucGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2rqfWlEPTB;MD6wO\|I1QCEQvF2=	MmfvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
HCE-T	MnW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUmyVYR4UUN3ME2xMlMzOjR5IN88US=>	MmD2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
D-542MG	NH\DSWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIXMSVRKSzVyPUGuPFY4OzdizszN	NHnqOYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
23132-87	NHexU29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmfVTWM2OD12LkSwNVQ4KM7:TR?=	M1\j[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
HDLM-2	NYXNRWVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFHUUJRKSzVyPUiuNFQ4PjZizszN	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
ACN	NGL4ZZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWPJR\|UxRThwNUCxNFkh\|ryP	M4jT[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
HuO-3N1	M4TqWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHPySodKSzVyPUmuOlAyODhizszN	Mon2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
BHT-101	NX\DVW4zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3rXOmlEPTB;MUGuN\|gh\|ryP	MnrjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
KYSE-150	M1;NUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2m2[GlEPTB;MUGuOVg1OSEQvF2=	MkTJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
MC-IXC	NHLSPVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NEPKOYdKSzVyPUGyMlIzQTJizszN	M2njdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
D-423MG	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYi1PWFtUUN3ME2xNk44PjV5IN88US=>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
NY	Mmj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXPJR\|UxRTF2Lki5NFMh\|ryP	M4DzSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
HOS	MojtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NGXUPZFKSzVyPUG1MlY4OTlizszN	M{P6V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
NB7	NUTFXIxpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXXJR\|UxRTF3Lki5NUDPxE1?	NWDPUGE4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd\|NEG3M{c,W0GQR1XSQE9iRg>?
DMS-273	NEjjVpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIHNOVNKSzVyPUG2MlY4OTNizszN	Ml3DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
MDA-MB-361	M3zINGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NX\qZlZ2UUN3ME2xO{4zPzFzIN88US=>	MnHPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
DU-145	M{LHXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MUDJR\|UxRTF6LkOyJO69VQ>?	NX6zfFhvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd\|NEG3M{c,W0GQR1XSQE9iRg>?
NCI-H82	NH\2WoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGriV29KSzVyPUG5Mlg{QDZizszN	M3j1e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
NCI-SNU-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2HyO2lEPTB;MkCuNFE6PiEQvF2=	M4j2W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
GCT	M332cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHLJe4ZKSzVyPUKwMlg5OjRizszN	M{fncFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
C2BBe1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1v4eGlEPTB;MkGuNVA2QCEQvF2=	Mn[2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
LB2241-RCC	NWXZ[FliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFT2XI5KSzVyPUKxMlg1PDFizszN	NWjlTndZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd\|NEG3M{c,W0GQR1XSQE9iRg>?
COLO-829	MnPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NYDmWVd2UUN3ME2yNk4yQDdzIN88US=>	NW\qZmJxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd\|NEG3M{c,W0GQR1XSQE9iRg>?
EW-11	NGnlTFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYe0TYsxUUN3ME2yNk45ODJ{IN88US=>	Mm[wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
NCI-H526	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVTDbFF7UUN3ME2yN{41PzF5IN88US=>	NETETGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
SF295	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2j0emlEPTB;MkSuNFI2OiEQvF2=	NWHBPI95RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd\|NEG3M{c,W0GQR1XSQE9iRg>?
D-566MG	NXjmbpZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MknETWM2OD1{NT6yPVQ{KM7:TR?=	M{DQflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
8505C	NYfQclJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWDJR\|UxRTJ3Lk[zN\|Eh\|ryP	NF3sdlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
HT-29	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MWDJR\|UxRTJ4LkC0N\|Eh\|ryP	NFP6TYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
NBsusSR	NF;2NYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmnrTWM2OD1{Nj64NFA3KM7:TR?=	MoOxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
BV-173	NFuzXIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MY\JR\|UxRTJ6LkOxPFIh\|ryP	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
CTB-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MX;JR\|UxRTNyLkGwN\|Eh\|ryP	NYHyfIFERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd\|NEG3M{c,W0GQR1XSQE9iRg>?
JAR	MoO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Ml6xTWM2OD1\|Mj61N\|cyKM7:TR?=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
CAMA-1	MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVfJR\|UxRTN\|LkS2NVUh\|ryP	M1TpN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
CAL-51	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVvJR\|UxRTN2LkexO\|Yh\|ryP	MnHtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
A172	NIe3OWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWOye3lUUUN3ME2zO{41QTJzIN88US=>	M3zNN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
QIMR-WIL	NHfmXXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2fCVGlEPTB;M{iuNFcxQCEQvF2=	NH[1S\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
AsPC-1	Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MYjJR\|UxRTN6LkS2OVEh\|ryP	NXLLPHp5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd\|NEG3M{c,W0GQR1XSQE9iRg>?
MKN7	NYLMNWNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVj4d\|VHUUN3ME2zPU4xODd7IN88US=>	MmfxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
ONS-76	Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXjaRox[UUN3ME20N{4{ODV5IN88US=>	M3XzWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
RS4-11	NFrsOopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MoLBTWM2OD12ND6wO\|UzKM7:TR?=	M37yV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
NOS-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M{jhemlEPTB;NESuOlA{OSEQvF2=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O\|M1OTdxJ{7TRW5ITVJ:L3G+
A101D	M1rDSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NETCeFhKSzVyPUS0MlgxOjNizszN	NIf5VIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
HCC1806	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mn3oTWM2OD12Nj6xNVQ5KM7:TR?=	M4jyN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
CAL-27	NUTQXppQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXLJR\|UxRTR5LkeyOFYh\|ryP	M{jZe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
BT-549	NWe5S4NiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3v3UGlEPTB;NEiuOVMyPSEQvF2=	NX3LNoZmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd\|NEG3M{c,W0GQR1XSQE9iRg>?
LCLC-97TM1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWHvPY5YUUN3ME20PU4zPDF\|IN88US=>	Mn;VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
A4-Fuk	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWrpSoxrUUN3ME20PU45PDlizszN	NHz5S5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK\|5USU6JRWK8M4E,
OVCAR-4	NHHJSmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUO4eohGUUN3ME21NE4xPjBzIN88US=>	M2H5blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
HD-MY-Z	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHv2XotKSzVyPUWwMlc4PjRizszN	Mlr4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
NCI-H292	NWnlNGg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NG[4[5lKSzVyPUWwMlg4PThizszN	MnOwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
Sk-ChA-1	MnnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PXWVAvOjYkgKO1NEDPxE1?	NIjGfYw4OiCq	M3P1XGlEPTB;N{SuOVTDuTJwNUlOwG0>	MmnWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NEK0PFIoRjJ3N{SyOFgzRC:jPh?=
Mz-ChA-1	NWr3[oVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LlclAvOjYkgKO1NEDPxE1?	MWC3NkBp	MonJTWM2OD13ND65O:KyOy52Nd88US=>	NX\Yd4k4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OFI1QDJpPkK1O\|QzPDh{PD;hQi=>
Smo-WT	M3rsVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnLPTWM2OMLib3[gNVTDqG6P	NIqwTnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK5NVExPCd-MkSyPVEyODR:L3G+
Smo-D473H	NIDx[GlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVjJR\|UxyqCxZjC3MlHDqM7:TR?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ7MUGwOEc,OjR{OUGxNFQ9N2F-
K562	NXzYZ2dQTnWwY4Tpc44hSXO\|YYm=	Ml[5NVAh\|ryP	NHTPSZo4OiCq	MXry[YR2[2W\|IITo[UBmgHC{ZYPzbY9vKG:oIFfsbVHDqA>?	M4fBW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{G5PFI1Lz5{M{OxPVgzPDxxYU6=
T315I BCR-ABL BaF3	M4PPPGZ2dmO2aX;uJGF{e2G7	NYi0eGRoOTBizszN	MXm3NkBp	M{fFU5Jm\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gS4xqOcLi	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzOUiyOEc,OjN\|MUm4NlQ9N2F-
TF-1 BCR-ABL	MlvySpVv[3Srb36gRZN{[Xl?	MnTGNVAh\|ryP	M3PufVczKGh?	NITxUFBz\WS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGdtcTIEoB?=	M2noVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{G5PFI1Lz5{M{OxPVgzPDxxYU6=
Shh-Light 2	NHzFcpJHfW6ldHnvckBie3OjeR?=		M1TOOVIh\GG7cx?=	MYDBcpRi\2:waYP0JIFkfGm4aYT5JIF1KFOvbzDpckBud3W\|ZTDTbIguVGmpaISgNkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGPobE1qdmS3Y3XkJGdtcTFvcnXwc5J1\XJiYXP0bZZqfHliYX\0[ZIhOiCmYYnzJIJ6KGS3YXytcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIH3leIhw\CxiSVO1NEA:KDBwMECxOUDPxE1w	NF3TNVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2N\|UzOid-MkOwOlM2OjJ:L3G+
NIH/3T3	NHq3NFJHfW6ldHnvckBie3OjeR?=			MnfYTY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC\|aXfuZYxqdmdiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gcY92e2ViTlnIM\|NVOyClZXzsd{BjgSCJbHmt[JVidC2udXPp[oVz[XOnIILldI9zfGW{IHHzd4F6NCCLQ{WwJF0hOC5yMEKzJO69VS5?	M3m2NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUiwNFEzLz5{N{G4NFAyOjxxYU6=
NIH/3T3 Light2	MlHESpVv[3Srb36gZZN{[Xl?			MljoTY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC\|aXfuZYxqdmdicHH0bJdigSCrbjDtc5V{\SCQSVivN3Q{KEyrZ3j0NkBk\WyuczDifUBIdGlvbIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBKSzVyIE2gNE4xODJ\|IN88UU4>	NHzF[VY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[4PFI4QCd-Mki2PFgzPzh:L3G+
Light2	NX;VWpdUTnWwY4Tpc44h[XO\|YYm=		MoXIOFghcHK\|	NWfJfm9VUW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W\|ZTDMbYdpfDJiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JGdtcS2udXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGlEPTBiPTCwMlAxOjR4IN88UU4>	M{[2UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{O5O\|E1Lz5{OUezPVcyPDxxYU6=
HEPM	MYjGeY5kfGmxbjDhd5NigQ>?			Ml[xTY5pcWKrdHnvckBw\iCVSFigbY4hcHWvYX6gTGVRVSClZXzsd{BjgSCJbHmtcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCLTligQUAxNjByMkig{txONg>?	M2LvOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{G2Nlk3Lz5zOUexOlI6PjxxYU6=
Shh Light2	M1u2UGZ2dmO2aX;uJIF{e2G7			NV;hVldRUW6qaXLpeIlwdiCxZjDTTGghcW5ibX;1d4UhW2iqIFzp[4h1OiClZXzsd{BjgSCJTFmtdoV{eG:wc3n2[UBncXKnZnz5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiSVO1NEA:KDBwMECzJO69VS5?	Ml3mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl\|MEmwPFAoRjF7M{C5NFgxRC:jPh?=
HEPM	M4LxcGZ2dmO2aX;uJIF{e2G7			MmSwTY5pcWKrdHnvckBw\iCKZXTn[Yhw\yC\|aXfuZYxqdmdiaX6gbJVu[W5iSFXQUUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5icnXj[ZB1d3JvbXXkbYF1\WRiR3zpNUBuWk6DIHX4dJJme3Orb36gZpkhemWyb4L0[ZIh\2WwZTDhd5NigSxiSV7IJF0hOC5yMEOg{txONg>?	Mon4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6N{W3OFEoRjJyOEe1O\|QyRC:jPh?=
C3H10T1/2	MoTQSpVv[3Srb36gZZN{[Xl?		NYnxVFZOOjBiaILz	NGD6XpdKdmirYnn0bY9vKG:oIGPtc{BqdiCvb4Xz[UBEO0hzMGSxM\|Ih[2WubIOgeZNqdmdiaIXtZY4hemWlb33ibY5idnRiU1jIJIF{e2W\|c3XkJIF{KGWoZnXjeEBwdiCVTV:vV2hJKHS{YX7zbYVvfCC2cnHud4NzcXC2aX;uZYwh[WO2aY\heIlwdiCjZoTldkAzOCCqcoOgZpkhT2yrLXz1Z4ln\XKjc3WgdoVxd3K2ZYKgZZN{[XluIFnDOVAhRSByLkCwOUDPxE1w	NUTCeG1ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA1OzZpPkK0PVAxPDN4PD;hQi=>
NIH/3T3	Ml\VSpVv[3Srb36gZZN{[Xl?		NHLNe2IzPCCqcoO=	MkfDTY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC\|aXfuZYxqdmdicHH0bJdigSCrbjDtc5V{\SCQSVivN3Q{KGOnbHzzJI1m[XO3cnXkJIFnfGW{IEK0JIhzeyCkeTDHcIku\HWjbDDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEmFNUCgQUAxNjByNTFOwG0v	NGmw[Yg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{ixNFU6OSd-Mke4NVA2QTF:L3G+
NIH3T3	MVjGeY5kfGmxbjDhd5NigQ>?		M3LDVFQ5KGi{cx?=	NWntRnVqUW6qaXLpeIlwdiCxZjDzcY8udWWmaXH0[YQhcGWmZ3Xoc4che2mpbnHsbY5oKHCjdHj3ZZkhcW5ibX;1d4UhVkmKM2SzJINmdGy\|IHX4dJJme3OrbnegS3JGNUy3YzDy[ZBwenSncjDn[Y5mKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhW0GJLXnu[JVk\WRiR2LFMWx2[yC{ZYDvdpRmeiCjY4Tpeol1gSCjZoTldkA1QCCqcoOgZpkhdHWvaX7ld4NmdmOnIHHzd4F6NCCLQ{WwJF0hOC5yME[g{txONg>?	NEPGOmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS5PVQ5Oyd-Mkm0PVk1QDN:L3G+
Shh-light2	MWPGeY5kfGmxbjDhd5NigQ>?			MnHkTY5pcWKrdHnvckBw\iCVbX:tcYVlcWG2ZXSgTIghe2mpbnHsbY5oKGmwIHj1cYFvKFOqaD3sbYdpfDJiY3XscJMh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBKSzVyIE2gNE4xODdizszNMi=>	NH3QUI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK2PFU2OSd-MkKyOlg2PTF:L3G+
HEK293	NEPB[HpHfW6ldHnvckBie3OjeR?=		NVXK[FJtOiCqcoO=	MVzEbZNxdGGlZX3lcpQhd2ZiQl;ETXB[NWyjYnXscIVlKGO7Y3zvdIFucW6nIH\yc40hcHWvYX6gV41wKHKnY3XweI9zKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[W[2ZYKgNkBpenNiYomg[ox2d3Knc3PlcoNmKG2rY4Lvd4NweHluIFnDOVAhRSByLkCwO{DPxE1w	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ4OEW1NUc,OjJ{Nki1OVE9N2F-
NIH3T3	MnmwSpVv[3Srb36gZZN{[Xl?			Mn76TY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC{ZXPldJRweiC\|aXfuZYxqdmdicHH0bJdigSCrbjDtc5V{\SCQSVizWFMh[2WubIOgeJJidnOoZXP0[YQhf2m2aDDHcIkuemWyb4L0[ZIh\2WwZTDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFnDOVAhRSByLkCwO\|E4KM7:TT6=	Mmn5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MkO3OlUoRjJ2OUKzO\|Y2RC:jPh?=
NIH/3T3	MlzMSpVv[3Srb36gZZN{[Xl?		M4rZU\|Q5KGi{cx?=	MoDnTY5pcWKrdHnvckBw\iCKZXTn[Yhw\yC\|aXfuZYxqdmdicHH0bJdigSCrbjDtc5V{\SCQSVivN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDTc45q[yCqZXTn[Yhw\y2rbnT1Z4VlKEeuaTDseYNq\mW{YYPlJIFkfGm4aYT5JIFnfGW{IES4JIhzeyCkeTDEeYFtNWy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygTWM2OCB;IECuNFA4OTdizszNMi=>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJ2OUS5OEc,OzB{NEm0PVQ9N2F-
NIH3T3	NHnzfo1HfW6ldHnvckBie3OjeR?=		MV20PEBpenN?	MVfJcohq[mm2aX;uJI9nKGinZHflbI9oKHOrZ37hcIxqdmdiaX6gcY92e2ViTlnIN3Q{KGOnbHzzJJN1[WKueTD0doFve2[nY4Tl[EB4cXSqIFfsbU1tfWOrZnXyZZNmKGOxboP0dpVkfCCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBlfWGuIHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhUUN3MDC9JFAvODB5MjFOwG0v	NFj6[4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkiyO\|E{Pid-Mk[4NlcyOzZ:L3G+
NIH3T3	MmD3SpVv[3Srb36gZZN{[Xl?		NYHjU5c{PDhiaILz	M1j1dGlvcGmkaYTpc44hd2ZiU3;ubYMucW6mdXPl[EBp\WSpZXjv[{B{cWewYXzsbY5oKGmwIH3veZNmKE6LSEPUN{Bk\WyuczDh[pRmeiB2ODDodpMh[nliR3zpMYx2[2moZYLhd4UhemWyb4L0[ZIh[XO\|YYmsJGlEPTBiPTCwMlAxPzJizszNMi=>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjh{MEW1OEc,OjZ6MkC1OVQ9N2F-
NIH3T3	M1POVGZ2dmO2aX;uJIF{e2G7		NX7vPJdKPDhiaILz	MkTvTY5pcWKrdHnvckBw\iCVSFigd4lodmGuaX7nJJBifGi5YYmgbY4hdW:3c3WgUmlJO1R\|IHPlcIx{KG2nYYP1doVlKGGodHXyJFQ5KGi{czDifUBIdGlvbIXjbYZmemG\|ZTDy[ZBwenSncjDhd5NigSxiSVO1NEA:KDBwMEC3NkDPxE1w	NX:0eoZSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxO\|Y{QTZpPkK0NVc3Ozl4PD;hQi=>
NIH/3T3	NXvnS2I1TnWwY4Tpc44h[XO\|YYm=		NH3qfXY1QCCqcoO=	MmntTY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC\|aXfuZYxqdmdicHH0bJdigSCrbjDtc5V{\SCQSVivN3Q{KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDHcIkudHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR\|UxKD1iMD6wNFczKM7:TT6=	MlXhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2OE[yNFMoRjJ2NEi2NlA{RC:jPh?=
NIH/3T3	MYTGeY5kfGmxbjDhd5NigQ>?			NYS4XGI1UW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W\|ZTDOTWgwO1R\|IHPlcIx{KGK7IFfsbVEudHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR\|UxKD1iMD6wNFczKM7:TT6=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRyNUewOEc,OjR2MEW3NFQ9N2F-
NIH/3T3	MV3GeY5kfGmxbjDhd5NigQ>?			NIHnbWFKdmirYnn0bY9vKG:oIHjl[IdmcG:pIIPp[45idGmwZzDwZZRpf2G7IHnuJI1wfXOnIF7JTE8{XDNiY3XscJMh[2G{conpcoche3SjYnz5JJRz[W6\|ZnXjeIVlKEeuaT3y[ZBwenSncjDjc45{fHK3Y4SgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCjc4PhfUwhUUN3MDC9JFAvODB5MjFOwG0v	MlHaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4NEKxNFEoRjJ6NkSyNVAyRC:jPh?=
C3H10T1/2	M3fyXGZ2dmO2aX;uJIF{e2G7		M2\rd\|YhcHK\|	MnLvTY5pcWKrdHnvckBw\iCVQVetbY5lfWOnZDDkbYZn\XKnboTpZZRqd25ib3[gcY92e2VibXXz[Y5kcHmvYXygdIx2emmyb4TlcpQhSzOKMUDUNU8zKGOnbHzzJJRwKGGua3HsbY5mKHCqb4PwbIF1[XOnIIDvd4l1cX[nIH;ld4Vw[myjc4TzJIFnfGW{IE[gbJJ{NCCLQ{WwJF0hOC5yMUGg{txONg>?	NVzSW\|VbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyOlg2PTFpPkKyNlY5PTVzPD;hQi=>
HCC827	MWrGeY5kfGmxbjDhd5NigQ>?			MXLEbZNxdGGlZX3lcpQhd2ZiW{PIYU1kgWOub4DhcYlv\SCocn;tJHNOVyCYNEC0UUBufXSjboSgbY4h\2WoaYTpcoljKHKnc3nzeIFvfCCqdX3hckBJS0N6MkegZ4VtdHNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiS3mgQUAxNjBzMkKg{txONg>?	M2Hve\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{i3NVU3Lz5{OEe4O\|E2PjxxYU6=
C3H10T1/2	MoTOSpVv[3Srb36gZZN{[Xl?			Ml3UTY5pcWKrdHnvckBw\iCVSFigbY4hdW:3c3WgR\|NJOTCWMT:yJINmdGy\|IHL5JGdtcS2udXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGlEPTBiPTCwMlAyOyEQvF2u	NWDtNndzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3NVYzQTZpPkG5O\|E3Ojl4PD;hQi=>
S12	NVfWUZJlTnWwY4Tpc44h[XO\|YYm=			MoT2TY5pcWKrdHnvckBw\iCKZXTn[Yhw\yC\|aXfuZYxqdmdiaX6gcY92e2ViU{GyJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiC{ZXPldJRwei2vZXTpZZRm\CCJbHmxJI1TVkFiZYjwdoV{e2mxbjDifUBz\XCxcoTldkBo\W6nIHHzd4F6NCCLTligQUAxNjBzMzFOwG0v	NGT4fog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEi3OVc1OSd-MkC4O\|U4PDF:L3G+
TM3	M1X3[mZ2dmO2aX;uJIF{e2G7		MXi0PEBpenN?	NFmwSFFKdmirYnn0bY9vKG:oIFjoJJNq\26jbHnu[{Bx[XSqd3H5JIlvKG2xdYPlJHROOyClZXzsd{Bie3Onc4Pl[EBieyCmb4fudoVofWyjdHnvckBw\iCJbHmxJIdmdmViZYjwdoV{e2mxbjDh[pRmeiB2ODDodpMh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBGSzVyIE2gNE4xOTNizszNMi=>	M3ryU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUe2NlE2Lz5{Nkm3OlIyPTxxYU6=
NIH/3T3	NGDEcHhHfW6ldHnvckBie3OjeR?=			M3;MPWlvcGmkaYTpc44hd2ZiaHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XliaX6gcY92e2ViTlnIM\|NVOyClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCVbX:gZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIFfsbUBuWk6DIHX4dJJme3Orb36gZpkhWlRvUFPSJI1mfGixZDygTWM2OCB;IECuNFE1PCEQvF2u	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzhzMEW5NUc,Ojd6MUC1PVE9N2F-
S12	M{XncWZ2dmO2aX;uJIF{e2G7		NUjXeoZRPDhiaILz	Mn;2TY5pcWKrdHnvckBw\iCqdX3hckBUUEhicHH0bJdigSCrbjDtc5V{\SCVMUKgZ4VtdHNiYYPz[ZN{\WRiYYOgS2xKNW2nZHnheIVlKHS{YX7zZ5JqeHSrb37hcEBi[3Srdnn0fUBi\nSncjC0PEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCLQ{WwJF0hOC5yMUWg{txONg>?	NWrNW2RNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0N\|g2OjdpPkKxOFM5PTJ5PD;hQi=>
NIH/3T3	M13OemZ2dmO2aX;uJIF{e2G7			NGTIU4hKdmirYnn0bY9vKG:oIGPNU{BqdiCvb4Xz[UBPUUhxM2SzJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiU1HHMYlv\HWlZXSgbIVl\2Wqb3etcYVlcWG2ZXSgcJVucW6nc3PlcoNmKHOrZ37hcIlv\yCkeTDHVmUudHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR\|UxKD1iMD6wNVYh\|ryPLh?=	NHLpS\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGxPVUxOCd-Mk[xNVk2ODB:L3G+
U2OS	MYjGeY5kfGmxbjDhd5NigQ>?		NUjNPGRjOiCqcoO=	MoDWSIl{eGyjY3Xt[Y51KG:oIGuzTH1kgWOub4DhcYlv\SCocn;tJJdqdGRidInw[UBUdW9iZYjwdoV{e2WmIHnuJHUzV1NiY3XscJMh[W[2ZYKgNkBpenNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiS3mgQUAxNjBzNkKg{txONg>?	M3rkOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|ME[zOVIzLz5{M{C2N\|UzOjxxYU6=
NIH3T3	NHyw[GJHfW6ldHnvckBie3OjeR?=		NGTBfYI{OCCqcoO=	M3jOdmlvcGmkaYTpc44hd2ZiU33vJJJm[2WydH;yJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKE6LSEPUN{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGPtc{Bi\2:waYP0JHNCTy2rbnT1Z4VlKEeURTDhZ5RqfmG2aX;uJIFnfGW{IEOwJIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEmFNUCgQUAxNjB{MzFOwG0v	NXzRVmZ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3NlY5ODdpPkK0O\|I3QDB5PD;hQi=>
medulloblastoma cell	MWnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MUOzOkBpenN?	NE\ld\|dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JHB1[2htLz2gZY5lKHB3Mz2vMUBud3W\|ZTDt[YR2dGyxYnzhd5RwdWFiY3XscJMh[W[2ZYKgN\|YhcHK\|IHL5JGJz\HViaX7jc5Jxd3KjdHnvckBie3OjeTygTWM2OCB;IECuNFMxPCEQvF2u	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ6OEK3PEc,Ojh4OEiyO\|g9N2F-
Shh Light2	M17K[mZ2dmO2aX;uJIF{e2G7			Mn3TRY51[WexbnnzeEBi[3Srdnn0fUBifCC\|bX;veIhmdmWmIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIGPobEBNcWeqdEKgZ4VtdHNiY3:t[ZhxemW\|c3nu[{BIdGlvZHXw[Y5l\W62IILldI9zfGW{IHflcoUh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBJcCC\|aXfuZYxqdmdiYomg[JVidCCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGlEPTBiPTCwMlA{OyEQvF2u	M4jnd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEmxOFU6Lz5{NES5NVQ2QTxxYU6=
Light2	NULBdWc{TnWwY4Tpc44h[XO\|YYm=			NULwNGN6UW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W\|ZTDMbYdpfDJiY3XscJMhcW5iU3joJINwdmSrdHnvcoVlKG2nZHn1cUBjgSCJbHmtcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCLQ{WwJF0hOC5yM{mg{txONg>?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh5M{OwN{c,Ojh6N{OzNFM9N2F-
Shh Light2	MlHWSpVv[3Srb36gZZN{[Xl?			MnW2TY5pcWKrdHnvckBw\iCVbX:tcYVlcWG2ZXSgTIghe2mpbnHscIlv\yCyYYToe4F6KGmwIH3veZNmKFOqaDDMbYdpfDJiY3XscJMh[nliR3zpMYx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiSVO1NEA:KDBwMEO5NkDPxE1w	M2[yfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{O2NFY{Lz5{N{ezOlA3OzxxYU6=
ASZ001	Mmq1SpVv[3Srb36gZZN{[Xl?		MWO0PEBpenN?	NGLqb25KdmirYnn0bY9vKG:oIFjl[IdmcG:pIIPp[45idGmwZzDpckBud3W\|ZTDBV3oxODFiY3XscJMh[XO\|ZYPz[YQh[XNiZH;3cpJm\3WuYYTpc44hd2ZiR3zpNUBuWk6DIHX4dJJme3Orb36gZYZ1\XJiNEigbJJ{KGK7IGLUMXBEWiCjbnHsfZNqeyxiSVO1NEA:KDBwMESg{txONg>?	NGq3fXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFcyPid-MkS5NFA4OTZ:L3G+
NIH/3T3	M4XaSmZ2dmO2aX;uJIF{e2G7		MWG0PEBpenN?	NH7jdmtCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IGPtc{Bz\WOncITvdkBqdiCvb4Xz[UBPUUhxM2SzJINmdGy\|IHjhdoJwemmwZzDHVmUuVHWlIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiU1HHMYlv\HWlZXSgTIghe2mpbnHsbY5oKHCjdHj3ZZkheHKnaX7jeYJifGWmIIfpeIgh[2WubIOg[o9tdG:5ZXSgZpkhW0GJIHHk[Il1cW:wIH3lZZN2emWmIHHmeIVzKDR6IHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGlEPTBiPTCwMlA1PiEQvF2u	MmPFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6NUeyO\|UoRjJ7OEW3Nlc2RC:jPh?=
Light2	M4HFOWZ2dmO2aX;uJIF{e2G7		NEOwcW8{OCCqcoO=	MXLJcohq[mm2aX;uJI9nKGinZHflbI9oKHOrZ37hcIlv\yCyYYToe4F6KGmwIH3veZNmKEyrZ3j0NkBk\WyuczDpckBUcGhiY3;u[Il1cW:wZXSgcYVlcXWvIHHmeIVzKDNyIHjyd{BjgSCJbHmtVoVvcWyuYTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEmFNUCgQUAxNjB3IN88UU4>	NFy5SIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC5PVI2Pyd-M{CwPVkzPTd:L3G+
C3H10T1/2	MoHLSpVv[3Srb36gZZN{[Xl?		MkO3OkBl[Xm\|	M1PhWmlvcGmkaYTpc44hd2ZiaHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XlvbXXkbYF1\WRiZHnm[oVz\W62aXH0bY9vKG:oIH3veZNmKEN\|SEGwWFEwOiClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDTRWcucW6mdXPl[EBCVFBiYXP0bZZqfHliYX\0[ZIhPiCmYYnzJIJ6KGOqZX3pcJVucW6nc3PlcoNmNWKjc3XkJIF{e2G7LDDJR\|UxKD1iMD6wOUDPxE1w	NHryWYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC5PVI2Pyd-M{CwPVkzPTd:L3G+
DaOY	NUnlW4l1TnWwY4Tpc44h[XO\|YYm=		NVLXUIEyPDhiaILz	MVfJcohq[mm2aX;uJI9nKEinZHflbI9oKHOrZ37hcIlv\yCrbjDoeY1idiCGYV;ZJINmdGy\|IHHzd4V{e2WmIHHzJIRwf26{ZXf1cIF1cW:wIH;mJGdtcTFibWLORUBmgHC{ZYPzbY9vKGGodHXyJFQ5KGi{czDifUBTXC2SQ2KgZY5idHm\|aYOsJGlEPTBiPTCwMlA5PiEQvF2u	M3[0dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwO\|E3Lz5{NEmwNFcyPjxxYU6=
C3H10T1/2	MWrGeY5kfGmxbjDhd5NigQ>?		NXW2cHpTOSCqch?=	NVXTdpV7UW6qaXLpeIlwdiCxZjDI[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W\|ZTDDN2gyOFRzL{KgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKHC3cn3vdpBp[W2rbnWtbY5lfWOnZDDpcoNz\WG\|ZTDpckBidGujbHnu[UBxcG:\|cHjheIF{\SCuZY\lcEB2e2mwZzDDSHAue3SjcjDhd{B{fWK\|dILheIUheHKndILlZZRm\CCob4KgNUBpeiCob3zsc5dm\CCkeTDweZJud3KyaHHtbY5mKGGmZHn0bY9vKG2nYYP1doVlKGGodHXyJFUh\GG7LDDJR\|UxKD1iMD6xOEDPxE1w	M4rmW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUS3PVM6Lz5{OEm0O\|k{QTxxYU6=
M210B4	M3fFZmZ2dmO2aX;uJIF{e2G7		NUXEV\|VFOjRiaILz	MkXJTY5pcWKrdHnvckBw\iCKZXTn[Yhw\yC\|aXfuZYxqdmdiaX6gcY92e2ViTUKxNGI1KGOnbHzzJIF{e2W\|c3XkJIF{KGSxd37y[Yd2dGG2aX;uJI9nKFC2Y3igcXJPSSCneIDy[ZN{cW:wIHHmeIVzKDJ2IHjyd{BjgSCUVD3QR3Ih[W6jbInzbZMtKEmFNUCgQUAxNjF2IN88UU4>	NUjsb3h{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA4OTZpPkK0PVAxPzF4PD;hQi=>
M210B4	NYewTnZMTnWwY4Tpc44h[XO\|YYm=		MV:yOEBpenN?	MnPrTY5pcWKrdHnvckBw\iCKZXTn[Yhw\yC\|aXfuZYxqdmdiaX6gcY92e2ViTUKxNGI1KGOnbHzzJIF{e2W\|c3XkJIF{KGSxd37y[Yd2dGG2aX;uJI9nKEeuaUGgcXJPSSCneIDy[ZN{cW:wIHHmeIVzKDJ2IHjyd{BjgSCUVD3QR3Ih[W6jbInzbZMtKEmFNUCgQUAxNjJizszNMi=>	M1HhPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwO\|E3Lz5{NEmwNFcyPjxxYU6=
Shh Light2	NVfFeHJlTnWwY4Tpc44h[XO\|YYm=		NU\hdmNmOSCqch?=	M{\SPGlvcGmkaYTpc44hd2ZiSHXk[4Vpd2dic3nncoFtcW6pIHnuJI1wfXOnIGPobEBNcWeqdEKgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKHC3cn3vdpBp[W2rbnWtbY5lfWOnZDDHcIkhdWWmaXH0[YQhfHKjboPjdolxfGmxbnHsJIFkfGm4aYT5JJBz\XS{ZXH0[YQh\m:{IEGgbJIh\m:ubH;3[YQh[nlicIXycY9zeGijbXnu[UBi\GSrdHnvckBu\WG\|dYLl[EBi\nSncjC0PEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCLQ{WwJF0hOC57ODFOwG0v	NVjMeG1YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OFc6OzlpPkK4PVQ4QTN7PD;hQi=>
NIH/3T3	M2r5OmZ2dmO2aX;uJIF{e2G7			MV3Jcohq[mm2aX;uJI9nKGinZHflbI9oKHOrZ37hcIlv\yCyYYToe4F6KGmwIH3veZNmKE6LSD:zWFMh[2WubIOgbIFz[m:{aX7nJHNudyCGNEe3TEBufXSjboSgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIFfsbUBuWk6DIHX4dJJme3Orb36gZpkhWlRvUFPSJI1mfGixZDygTWM2OCB;IEGuNVk3KM7:TT6=	MmjBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6MUC1PVEoRjJ5OEGwOVkyRC:jPh?=
S12	MYPGeY5kfGmxbjDhd5NigQ>?		NVzk[FFCPDhiaILz	M17XOGlvcGmkaYTpc44hd2ZiaIXtZY4hW0iKIIDheIh4[XliaX6gcY92e2ViU{GyJINmdGy\|IHHzd4V{e2WmIHHzJGdNUS2vZXTpZZRm\CC2cnHud4NzcXC2aX;uZYwh[WO2aY\peJkh[W[2ZYKgOFghcHK\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSCrbjDwdoV{\W6lZTDv[kAxNjVibXevcWwhcHWvYX6gZYxxcGFvMT3hZ4llKGeueXPvdJJwfGWrbjygTWM2OCB;IEGuO\|Uh\|ryPLh?=	NWDDXlBiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0N\|g2OjdpPkKxOFM5PTJ5PD;hQi=>
Calu6	NWHYeVJSTnWwY4Tpc44h[XO\|YYm=		MmrpOEBpenN?	NE\H[5lRdGG\|bXGgZ49v[2WwdILheIlwdiCrbjDoeY1idiCFYXz1OkBk\WyuczD4[Y5w\3KjZoTl[EBqdiCwdXTlJI1wfXOnIHH0JFc2KG2pL3vnMEBxdyCkaXSgcYVie3W{ZXSgZYZ1\XJiNDDodpMheG:\|dDDmbYZ1cCCmb4PlMEBEeCB;IEKzJO69VS5?	MoHXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5MU[yPVYoRjF7N{G2Nlk3RC:jPh?=
Calu-6	NGXqbZpHfW6ldHnvckBie3OjeR?=			MkPlVIxie22jIHPvcoNmdnS{YYTpc44hcW5iQ3HseU03KGOnbHzzJJhmdm:pcnHmeIVlKG63ZHWgcY92e2ViUFuvVGQhdW:mZXygZZQhPzVibXevb4ctKHCxIHLp[EBnd3JiNTDkZZl{KG2nYYP1doVlKDRiaILzJJBwe3RibHHzeEBld3OnIILlcIF1cX[nIITvJJVvfHKnYYTl[EBkd262cn;sMEBEeCB;IEKzJO69VS5?	MlTTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6N{W3OFEoRjJyOEe1O\|QyRC:jPh?=
T47D	NXrtcYV3S3m2b4TvfIlkcXS7IHHzd4F6		NXnMXYlYPzJiaILz	MlzGR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWFQ4TCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gOFEvOzRizszNMi=>	NIfLPIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUGwO\|QzQSd-MkmxNFc1Ojl:L3G+
LS180	NIDiVmNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NFjFemM4OiCqcoO=	Ml3rRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCOU{G4NEBk\WyuczDh[pRmeiB5MjDodpMh[nlic4Xs[o9zcG:mYX3pcoUuSiCjc4PhfUwhUUN3MDC9JFQ2KM7:TT6=	NFn4S2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC5PVI2Pyd-M{CwPVkzPTd:L3G+
LS174T	NI\r[YpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		Mn\oO\|IhcHK\|	Mm\NRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCOU{G3OHQh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hdHWvaX7ld4NmdnRiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0OU45OSEQvF2u	M3vXOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OEKwOVU1Lz5{NkiyNFU2PDxxYU6=
BxPC3	NUTWeJFvSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M1\XXlczKGi{cx?=	NGm5cYhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFL4VGM{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGy3bXnu[ZNk\W62IHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOFcvQTVizszNMi=>	NGXk[Y89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkiyNFU2PCd-Mk[4NlA2PTR:L3G+
medulloblastoma cell	NILmbWdCdnSrdIXtc5Ih[XO\|YYm=			MYPBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCvZXT1cIxw[myjc4TvcYEh[2WubIOgfIVvd2e{YX\0[YQhcW5iUITjbEAsNy1ibX;1d4Uh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6geJVud3Jidn;seY1mKGG2IEGyMlUhdWdxa3esJJBwKGKrZD6=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTdzNkK5Okc,OTl5MU[yPVY9N2F-
S12	M3zOd2Z2dmO2aX;uJIF{e2G7		MWK0PEBpenN?	M3voZ2lvcGmkaYTpc44hd2ZiaIXtZY4hW0iKIIDheIh4[XliaX6gcY92e2ViU{GyJINmdGy\|IHHzd4V{e2WmIHHzJGdNUS2vZXTpZZRm\CC2cnHud4NzcXC2aX;uZYwh[WO2aY\peJkh[W[2ZYKgOFghcHK\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSCrbjDwdoV{\W6lZTDv[kAyKG2pL33MJIh2dWGwIHHsdIhiNTFvYXPp[EBodHmlb4Dyc5RmcW5w	Mmr5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2M{i1NlcoRjJzNEO4OVI4RC:jPh?=
Shh Light2	MoD6SpVv[3Srb36gZZN{[Xl?	NHPlWZYxNjFidV2=	MYCzOkBpenN?	MlrCTY5pcWKrdHnvckBw\iCVbX:tcYVlcWG2ZXSgTIghe2mpbnHscIlv\yCyYYToe4F6KGmwIH3veZNmKFOqaDDMbYdpfDJiY3XscJMh[XO\|ZYPz[YQh[XNic4XwdJJme3Orb36gc4YhT2yrMT3tVm5CKGW6cILld5Nqd25iYYSgNE4yKHWPIH3lZZN2emWmIHHmeIVzKDN4IHjyd{BjgSCUVD3xVGNTKGGwYXz5d4l{Ng>?	Mk\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5M{[wOlMoRjJ5N{O2NFY{RC:jPh?=
SW1353	M2W1Z2FvfGmycn;sbYZmemG2aY\lJIF{e2G7	NVTYTo86OTBidV2=	MkfSOFghcHK\|	MlXKRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVV{GzOVMh[2WubIOgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[XRiMUCgeW0h[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfU4>	NFvUSlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES5NVQ2QSd-MkS0PVE1PTl:L3G+
DaOY	NEPMSoNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=	MmC0NVAhfU1?	MlzLOFghcHK\|	MUfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESjT2mgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZZQhOTBidV2gZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeT6=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR7MUS1PUc,OjR2OUG0OVk9N2F-
A549	MXrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?	MljYNVAhfU1?	M{nrNFQ5KGi{cx?=	NEKxVIRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[XRiMUCgeW0h[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfU4>	NWPv[29sRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PVE1PTlpPkK0OFkyPDV7PD;hQi=>
HCT116	NFzhdo1CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=	MkXZNVAhfU1?	NYCwVG5vPDhiaILz	NV3FT5o{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYYSgNVAhfU1iYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigS5?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR7MUS1PUc,OjR2OUG0OVk9N2F-
NIH/3T3	Ml;4SpVv[3Srb36gZZN{[Xl?	M1rtO\|ExKHWP		NEDTU5hKdmirYnn0bY9vKG:oIFjl[IdmcG:pIIPp[45idGmwZzDpckBud3W\|ZTDOTWgwO1R\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTve44hemWpdXzheIlwdiCxZjDtVHREUDFibWLORUBmgHC{ZYPzbY9vKGG2IEGwJJVONg>?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR7MUS1PUc,OjR2OUG0OVk9N2F-
MSC	MUfGeY5kfGmxbjDhd5NigQ>?	M3jnR\|IxKHSxIEiwJJVO		MUPJcohq[mm2aX;uJI9nKGinZHflbI9oKHOrZ37hcIlv\yCrbjDtc5V{\SCPU1OgZ4VtdHNiYYPz[ZN{\WRiYYOg[I94diC{ZXf1cIF1cW:wIH;mJIFtc2GuaX7lJJBpd3OyaHH0ZZNmKGG2IEKwJJRwKDhyIIXNMi=>	NYHNT2liRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PVE1PTlpPkK0OFkyPDV7PD;hQi=>
SK-N-MC	M3r4OZFJXFNiYYPzZZk>			NYW3SGgyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJMv	M3;MclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
TC32	NGjrSlNyUFSVIHHzd4F6			MYHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDUR\|MzKGOnbHzzMi=>	M17aTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NIH3T3-Luc	M4LNVGZ2dmO2aX;uJIF{e2G7	MofWNUB2VQ>?	NUTweIYzPDhiaILz	NF;ybHZKdmirYnn0bY9vKG:oIIPtc{1u\WSrYYTl[EBp\WSpZXjv[{B{cWewYXzpcocheGG2aIfhfUBqdiCvb4Xz[UBPUUh\|VEOtUJVkKGOnbHzzJIF{e2W\|c3XkJIF{KGSxd37y[Yd2dGG2aX;uJI9nKEeuaTDtVm5CKGW6cILld5Nqd25iYYSgNUB2VSCjZoTldkA1QCCqcoOgZpkhemWjbD30bY1mKFCFUjDhcoFtgXOrcz6=	MkHFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2OUm0PFMoRjJ7NEm5OFg{RC:jPh?=
C3H10T1/2	NHrIfWZHfW6ldHnvckBie3OjeR?=		M3T1UFI1KGi{cx?=	MoPFTY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC\|aXfuZYxqdmdicHH0bJdigS2vZXTpZZRm\CCJTFmxJI1TVkFiZYjwdoV{e2mxbjDpckBud3W\|ZTDDN2gyOFRzL{KgZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KFKWLWDDVkBidmGueYPpd{BqdiCycnXz[Y5k\SCxZjCoNXItO2GULETTMFdiWilvN3GtcYV1cHmuLUGtLEhTMS14LX3leIh6dGincIThck0zNXmuKX;jeIFpgWS{bz2xTE1qdmSnbj20MZltKDNvaInkdo95gWKnborvZZRmNg>?	MoD4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5M{C5PFQoRjJ2N{OwPVg1RC:jPh?=
C3H10T1/2	M1[xN2Z2dmO2aX;uJIF{e2G7		NVvEd4liOjRiaILz	MmfyTY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC\|aXfuZYxqdmdicHH0bJdigS2vZXTpZZRm\CCJTFmxJI1TVkFiZYjwdoV{e2mxbjDpckBud3W\|ZTDDN2gyOFRzL{KgZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KFKWLWDDVkBidmGueYPpd{BqdiCycnXz[Y5k\SCxZjDWSFMv	NU\CVJZtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3N\|A6QDRpPkK0O\|MxQTh2PD;hQi=>
NIH/3T3	NILaNmdHfW6ldHnvckBie3OjeR?=	MXixNFAhdk1?	M4DycFM3KGi{cx?=	M2nQZWlvcGmkaYTpc44hd2ZiaHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XliaX6gcY92e2ViTlnIM\|NVOyClZXzsd{Bie3Onc4Pl[EBieyCmb4fudoVofWyjdHnvckBw\iCVaHitbY5lfWOnZDDHcIkyKG2UTlGg[ZhxemW\|c3nvckBt\X[nbIOgZZQhOTByIH7NJIFnfGW{IEO2JIhzeyCkeTDSWE1yWEOUIHHuZYx6e2m\|Lh?=	MkXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6N{OzNFMoRjJ6OEezN\|A{RC:jPh?=
C3H10T1/2	M4X6SGZ2dmO2aX;uJIF{e2G7	MWexNFAhdk1?	NFLscoQ{PiCqcoO=	MonzTY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC\|aXfuZYxqdmdicHH0bJdigSCrbjDtc5V{\SCFM1ixNHQyNzJiY3XscJMh[XO\|ZYPz[YQh[XNiZH;3cpJm\3WuYYTpc44hd2ZiU3joMYlv\HWlZXSgS4xqOSCvUl7BJIV5eHKnc4Ppc44hdGW4ZXzzJIF1KDFyMDDuUUBi\nSncjCzOkBpenNiYomgVnQueVCFUjDhcoFtgXOrcz6=	NGLwdlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi3N\|MxOyd-Mki4O\|M{ODN:L3G+
NIH/3T3	MUXGeY5kfGmxbjDhd5NigQ>?	MlvqNVAxKG6P	NY\B[YpyOzZiaILz	MW\Jcohq[mm2aX;uJI9nKGinZHflbI9oKHOrZ37hcIlv\yCyYYToe4F6KGmwIH3veZNmKE6LSD:zWFMh[2WubIOgZZN{\XO\|ZXSgZZMh\G:5boLl[5Vt[XSrb36gc4YhW2iqLXnu[JVk\WRicITjbFEhdVKQQTDlfJBz\XO\|aX;uJIxmfmWuczDheEAyODBibl2gZYZ1\XJiM{[gbJJ{KGK7IGLUMZFRS1JiYX7hcJl{cXNw	Mlz5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6N{OzNFMoRjJ6OEezN\|A{RC:jPh?=
C3H10T1/2	MXjGeY5kfGmxbjDhd5NigQ>?	NWnF[Fg2OTByIH7N	NIiyTnU{PiCqcoO=	M4LOdmlvcGmkaYTpc44hd2ZiaHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XliaX6gcY92e2ViQ{PINVBVOS9{IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTve45z\We3bHH0bY9vKG:oIGPobE1qdmS3Y3XkJJB1[2hzIH3SUmEh\XiycnXzd4lwdiCuZY\lcJMh[XRiMUCwJI5OKGGodHXyJFM3KGi{czDifUBTXC2zUFPSJIFv[Wy7c3nzMi=>	MoLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6N{OzNFMoRjJ6OEezN\|A{RC:jPh?=
medulloblastoma cell	M3\rbmFvfGmycn;sbYZmemG2aY\lJIF{e2G7	NGfNNHB2eCC2bzCzNEB2VQ>?	NUf1Z4hVPzJiaILz	NXXDbVNvSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDQeINpMy9vIIC1N{0wNSCvZXT1cIxw[myjc4TvcYEh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwheHKxbHnm[ZJifGmxbjD1dEB1dyB\|MDD1UUBi\nSncjC3NkBpenNiYomgUXRUKGG\|c3H5Mi=>	MlHEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6N{OzNFMoRjJ6OEezN\|A{RC:jPh?=
medulloblastoma cell	NXTrXnZRSXCxcITvd4l{KGG\|c3H5			MULJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIH3veZNmKFC2Y3irM{0heDV\|LT:tJI1m\HWubH;icIF{fG:vYTDj[YxteyCrbYDsZY51\WRiaX6gZZRpgW2rYzDueYRmKG2xdYPlJIF1KDF{LkWgcYcwc2duIHnwJIJq\CCob4KgNVUh[2:wc3XjeZRqfmViZHH5d{BjgSCWVV7FUEBie3OjeT6=	MoHtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6N{OzNFMoRjJ6OEezN\|A{RC:jPh?=
NIH/3T3	NGn2c4xHfW6ldHnvckBie3OjeR?=			NUCzdnVTUW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDlfJBz\XO\|ZXSgbY4hdW:3c3WgUmlJNzOWMzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGinZHflbI9oNWmwZIXj[YQhT2yrLUKgZYNkfW23bHH0bY9vKGG2IITpdEBw\iCycnntZZJ6KGOrbHnhJIJ6KESDUFmgd5RicW6rbnegZoF{\WRiY3;u[o9k[WxibXnjdo9{[2:yaXOgZY5idHm\|aYOu	MmDNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6MUC1PVEoRjJ5OEGwOVkyRC:jPh?=
NIH/3T3	MlqwSpVv[3Srb36gZZN{[Xl?			MlzQTY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC\|aXfuZYxqdmdicHH0bJdigSCrbjDtc5V{\SCQSVivN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gbIVl\2Wqb3etbY5lfWOnZDDTcY8uTUeIUDDjbYxq[XK7IITyZY5{dG:lYYTpc44h[nliRFHQTUB{fGGrbnnu[{Bj[XOnZDDjc45nd2OjbDDtbYNzd3Olb4DpZ{BidmGueYPpd{4>	M1;UUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OEGwOVkyLz5{N{ixNFU6OTxxYU6=
medulloblastoma cell	MWLBcpRqNXS3bX;yJIF{e2G7			MV;BcpRqNXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViUITjbEswNSCyNUOtM{0hdWWmdXzsc4Jt[XO2b33hJINmdGy\|IHntdIxidnSnZDDpckBifGi7bXnjJI52\GVibX;1d4Uh[XO\|ZYPz[YQh[XNidIXtc5Ih\3Kxd4ToJIlvcGmkaYTpc44h[XRiMkCgcYcwc2duIIDvJIFldWmwaYP0[ZJm\CC2d3nj[UBl[WmueTD2bYEh\2G4YXflJI1m[XO3cnXkJIV3\XK7IH;0bIVzKGSjeTDkeZJqdmdiY3;tdI92dmRiZH;zbY5oNg>?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd\|OUexOEc,Ojl5M{m3NVQ9N2F-
C3H10T1/2	MXPGeY5kfGmxbjDhd5NigQ>?	NFLWS5g1NjFidH:gNVAxOCCwTR?=		M{Hs[GFtdG:\|dHXybYMhcW6qaXLpeIlwdiCxZjDTcY8hcW5ibX;1d4UhSzOKMUDUNU8zKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gdJVzdW:{cHjhcYlv\S2rbnT1Z4VlKEeuaUGgeJJidnOlcnnweIlwdmGuIHHjeIl3cXS7IHH0JFQvOSC2bzCxNFAxKG6PIHL5JJFRS3JiYX7hcJl{cXNw	NIrIcFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C3OFU1OSd-MkOwO\|Q2PDF:L3G+
C3H10T1/2	NIjacItHfW6ldHnvckBie3OjeR?=	NGG3Z401NjFidH:gNVAxOCCwTR?=		NXO1e4ZNS2:vcHX0bZRqfmViaX7obYJqfGmxbjDv[kBUdW9iaX6gcY92e2ViQ{PINVBVOS9{IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhW0GJLXnu[JVk\WRiR3zpNUB1emGwc3PybZB1cW:wYXygZYN1cX[rdImgZZQhPC5zIITvJFExODBibl2gZpkheVCFUjDhcoFtgXOrcz6=	M3flfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEe0OVQyLz5{M{C3OFU1OTxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Bcl-2 / Bax; PubMed: 28195165 Sci Rep GDC-0449 treatment affected the expression levels of cell cycle-related protein levels. U251 cells were treated with 0.1% DMSO or GDC-0449 at the indicated concentrations for 24 h. Cells were then harvested and examined using Western blot analysis with the indicated antibodies. p53 / Cyclin D1 / p21; PubMed: 28195165 Sci Rep GDC-0449 treatment affected the expression levels of cell cycle-related protein levels. U251 cells were treated with 0.1% DMSO or GDC-0449 at the indicated concentrations for 24 h. Cells were then harvested and examined using Western blot analysis with the indicated antibodies. Gli1 / SOX2 / OCT4; PubMed: 26418365 Stem Cells The activation of Hedgehog pathways and CSC markers were tested by immunoblotting analysis in Hs578T and BT549 cells. β‐Actin was used as a loading control. p-GSK3β / GSK3β / p-Akt / Akt / Gli1; PubMed: 27143997 Oxid Med Cell Longev Cells were pretreated with or without 30 μM GDC-0449 for 2 h before TMT treatment. After incubation with 3.75 μM TMT for another 24 h, the expression levels of proteins were determined through Western blot analysis. Fas / DR4 / DR5 / Cleaved PARP / Bcl-2 / Cleaved caspase-3 / PDGFRα; PubMed: 22087285 PLoS One Pancreatic CSCs were treated with GDC-0449 (0, 1, 5 and 10 µM) for 48 h. The expression of Fas, DR4/TRAIL-R1, DR5/TRAIL-R2, PARP cleavage, Bcl-2, and Caspase-3 by the Western blot analysis. β-Actin was used as a loading control.	28195165 26418365 27143997 22087285
Immunofluorescence	Gli1 / Gli2; PubMed: 22087285 PLoS One GDC-0449 inhibits expression of Gli1 and Gli2 in human pancreatic CSCs. The cells were seeded on fibronectin-coated coverslips and treated with GDC-0449 (10 µM) for 48 h. Subsequently, cells were fixed with 4% paraformaldehyde, blocked in 10% normal goat serum and stained with Gli1 and Gli2 primary antibodies (1∶100) for 16 h at 4°C and washed with PBS. Afterwards, cells were incubated with fluorescently labeled secondary antibody (1∶200) along with DAPI (1 mg/ml) for 1 h at room temperature and cells were mounted and visualized under a fluorescent microscope. For better visuality, the color of DAPI was changed from blue to red.	22087285
Growth inhibition assay	Cell viability; PubMed: 29042665 Sci Rep GDC-0449 improves the anti-proliferation activity in NIH-3T3 cells but not in BxPC-3, Panc-1, MIAPaca-2 and SW1990 cells when cultured alone. The cytotoxicities of GDC-0449, Dox or Dox with GDC-0449 (5 μM or 10 μM) were measured by performing a 48-h MTT assay in BxPC-3 (A), Panc-1 (B), MIAPaca-2 (C), SW1990 (D) and NIH-3T3 (E) cells. Apoptosis rate was detected by flow cytometry (Annexin V staining) analysis after treatment with Dox (200 nM) with or without GDC-0449 for 24 h (F). Data are presented as the mean ± SD. P < 0.05, *P < 0.01.	29042665

体内研究

GDC-0449已经用于治疗动物模型的成髓细胞瘤。^[2] GDC-0449 抑制原代胰腺移植瘤生长，但是不抑制细胞增殖。GDC-0449按25 mg/kg 以上剂量口服给药髓母细胞瘤Ptch(+/-)异体移植物模型，引起细胞衰退，按92 mg/kg剂量处理两种配位体依赖的结肠直肠癌模型D5123和1040830，每天处理两次，抑制肿瘤生长。分析Hh通路活性和 PK/PD 模型显示GDC-0449抑制 Gli1，IC50值与GDC-0449作用于髓母细胞瘤和D5123模型的IC50值差不多(分别为0.165 μM ±11.5% 和0.267 μM ±4.83%)。^[4]

细胞实验：^[2]	- 合并 Cell lines: MDCKII细胞 Concentrations: 20 μM Incubation Time: 2小时 Method: MDCKII细胞按每孔3x10⁵密度接种在24孔板中。培养液包含不同药物，实验组为50 µM VP,50 µM吲哚美辛,或者20 µM GDC-0449溶解在DMSO中，对照组只含有DMSO。然后加入非荧光的钙黄绿素-AM，最终浓度达到1.0 µM。然后在37^oC温育2小时。细胞用含Ca²⁺,Mg²⁺的Hank's平衡盐溶液buffer冲洗2次，然后震荡1小时溶解在含0.01% Triton X-100的磷酸缓冲液中，然后放在4^oC下过夜。溶解的物质然后转移到96孔板上，钙黄绿素引起的荧光信号用分光光度法定量。所有的实验操作需在暗中进行，所有的读数用平均值±SEM表示。 (Only for Reference)
动物实验：^[4]	- 合并 Animal Models: Ptch(+/-)异体移植物模型 Dosages: 25 mg/kg,92 mg/kg Administration: 口服 (Only for Reference)

参考文献

[4] Wong H, et al. Clin Cancer Res. 2011, 17(14), 4682-4692.

- 合并

溶解度 (25°C)

体外	DMSO	84 mg/mL (199.38 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O	12.5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Vismodegib (GDC-0449) SDF

分子量	421.3
化学式	C₁₉H₁₄Cl₂N₂O₃S
CAS号	879085-55-9
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03610022	Recruiting	Drug: Treatment with vismodegib	Metastatic Basal Cell Carcinoma\|Locally Advanced Basal Cell Carcinoma	University Hospital Bordeaux	September 3 2018	Phase 4
NCT03035188	Unknown status	Drug: Vismodegib	Basal Cell Carcinoma	SRH Wald-Klinikum Gera GmbH	January 2017	Phase 2
NCT02781389	Completed	--	Basal Cell Carcinoma	University Hospital Essen\|OnkoDataMed GmbH	April 29 2016	--
NCT02593760	Completed	Other: Placebo\|Drug: Ruxolitinib\|Drug: Vismodegib	Myelofibrosis	Hoffmann-La Roche	January 25 2016	Phase 1
NCT02648048	Completed	Drug: Pirfenidone\|Drug: Vismodegib	Idiopathic Pulmonary Fibrosis	Hoffmann-La Roche	January 15 2016	Phase 1
NCT02436408	Active not recruiting	Drug: Vismodegib	Carcinoma Basal Cell	University of Michigan Rogel Cancer Center	July 15 2015	Phase 4

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

用于临床的Smoothened抑制剂

LDE225 (NVP-LDE225,Erismodegib) : Phase III for Hh-pathway activated relapsed Medulloblastoma (MB).
最新的Smoothened抑制剂

GANT61 : Inhibitor for GLI1 as well as GLI2-induced transcription, inhibits hedgehog with IC50 of 5 μM, displays selectivity over other pathways, such as TNF and glucocorticoid receptor gene transactivation.
Smoothened激活剂

Purmorphamine : Directly binds and activates Smoothened, and blocks BODIPY-cyclopamine binding to Smo with IC50 of ~ 1.5 μM.

研究领域

产品类型

定制您的化合物库

Vismodegib (GDC-0449)

客户使用Selleck生产的Vismodegib (GDC-0449)发表文献153篇：

产品安全说明书

Hedgehog/Smoothened抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Vismodegib (GDC-0449) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

技术支持

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

相关Hedgehog/Smoothened产品